Millie Long
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Akhlaghpour M, Haritunians T, More S, Thomas L, Stamps D, Dube S, Li D, Yang S, Landers C, Mengesha E, Hamade H, Murali R, Potdar A, Wolf A, Botwin G, Khrom M, International IBD Genetics Consortium, Ananthakrishnan A, Faubion W, Jabri B, Lira S, Newberry R, Sandler R, Sartor R, Xavier R, Brant S, Cho J, Duerr R, Lazarev M, Rioux J, Schumm L, Silverberg M, Zaghiyan K, Fleshner P, Melmed G, Vasiliauskas E, Ha C, Rabizadeh S, Syal G, Bonthala N, Ziring D, Targan S, Long M, McGovern D, Michelsen K, Brand S. Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis. Gut 2023; 72:2068-2080.
Apr 20, 2023Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Apr 20, 2023Gut 2023; 72:2068-2080
Akhlaghpour Marzieh, Haritunians Talin, More Shyam K, Thomas Lisa S, Stamps Dalton T, Dube Shishir, Li Dalin, Yang Shaohong, Landers Carol J, Mengesha Emebet, Hamade Hussein, Murali Ramachandran, Potdar Alka A, Wolf Andrea J, Botwin Gregory J, Khrom Michelle, International IBD Genetics Consortium, Ananthakrishnan Ashwin N, Faubion William A, Jabri Bana, Lira Sergio A, Newberry Rodney D, Sandler Robert S, Sartor R Balfour, Xavier Ramnik J, Brant Steven R, Cho Judy H, Duerr Richard H, Lazarev Mark G, Rioux John D, Schumm L Philip, Silverberg Mark S, Zaghiyan Karen, Fleshner Phillip, Melmed Gil Y, Vasiliauskas Eric A, Ha Christina, Rabizadeh Shervin, Syal Gaurav, Bonthala Nirupama N, Ziring David A, Targan Stephan R, Long Millie, McGovern Dermot P B, Michelsen Kathrin S, Brand Stephan
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 7:128-140.
Nov 17, 2021Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Nov 17, 2021Lancet Gastroenterol Hepatol 2021; 7:128-140
Peyrin-Biroulet Laurent, Hart Ailsa, Bossuyt Peter, Long Millie, Allez Matthieu, Juillerat Pascal, Armuzzi Alessandro, Loftus Edward V, Ostad-Saffari Elham, Scalori Astrid, Oh Young S, Tole Swati, Chai Akiko, Pulley Jennifer, Lacey Stuart, Sandborn William J, HICKORY Study Group